Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 1
2011 1
2012 1
2013 2
2014 2
2015 2
2017 1
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response.
Fiori LM, Orri M, Aouabed Z, Théroux JF, Lin R, Nagy C, Frey BN, Lam RW, MacQueen GM, Milev R, Müller DJ, Parikh SV, Rotzinger S, Uher R, Foster JA, Kennedy SH, Turecki G. Fiori LM, et al. Transl Psychiatry. 2021 Aug 21;11(1):439. doi: 10.1038/s41398-021-01564-8. Transl Psychiatry. 2021. PMID: 34420030 Free PMC article.
In conclusion, using longitudinal assessments of gene expression, we provide insights into biological processes involved in the intermediate stages of escitalopram response, highlighting several genes with potential utility as biomarkers of antidepressant response.. …
In conclusion, using longitudinal assessments of gene expression, we provide insights into biological processes involved in the intermediate …
Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
Dunlop K, Rizvi SJ, Kennedy SH, Hassel S, Strother SC, Harris JK, Zamyadi M, Arnott SR, Davis AD, Mansouri F, Schulze L, Ceniti AK, Lam RW, Milev R, Rotzinger S, Foster JA, Frey BN, Parikh SV, Soares CN, Uher R, Turecki G, MacQueen GM, Downar J. Dunlop K, et al. Neuropsychopharmacology. 2020 Jul;45(8):1390-1397. doi: 10.1038/s41386-020-0688-x. Neuropsychopharmacology. 2020. PMID: 32349119 Free PMC article.
Escitalopram response is associated with clinical and neuroimaging correlates of reward processing. These results represent an important contribution towards identifying and integrating biological, behavioral, and clinical correlates of treatment respo …
Escitalopram response is associated with clinical and neuroimaging correlates of reward processing. These results repre …
Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics.
Ji Y, Hebbring S, Zhu H, Jenkins GD, Biernacka J, Snyder K, Drews M, Fiehn O, Zeng Z, Schaid D, Mrazek DA, Kaddurah-Daouk R, Weinshilboum RM. Ji Y, et al. Clin Pharmacol Ther. 2011 Jan;89(1):97-104. doi: 10.1038/clpt.2010.250. Epub 2010 Nov 24. Clin Pharmacol Ther. 2011. PMID: 21107318 Free PMC article. Clinical Trial.
Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response.
Powell TR, Schalkwyk LC, Heffernan AL, Breen G, Lawrence T, Price T, Farmer AE, Aitchison KJ, Craig IW, Danese A, Lewis C, McGuffin P, Uher R, Tansey KE, D'Souza UM. Powell TR, et al. Eur Neuropsychopharmacol. 2013 Sep;23(9):1105-14. doi: 10.1016/j.euroneuro.2012.09.009. Epub 2012 Nov 9. Eur Neuropsychopharmacol. 2013. PMID: 23142150 Clinical Trial.
In particular, protein levels of Tumor Necrosis Factor (TNF) and the SNPs rs1126757 in interleukin-11 (IL11), and rs7801617 in interleukin-6 (IL6), have previously been implicated in the clinical response to the selective serotonin reuptake inhibitor (SSRI) antidepressant …
In particular, protein levels of Tumor Necrosis Factor (TNF) and the SNPs rs1126757 in interleukin-11 (IL11), and rs7801617 in interleukin-6 …
Pre-treatment factor structures of the Montgomery and Åsberg Depression Rating scale as predictors of response to escitalopram in Indian patients with non-psychotic major depressive disorder.
Basu A, Chadda R, Sood M, Rizwan SA. Basu A, et al. Asian J Psychiatr. 2017 Aug;28:154-159. doi: 10.1016/j.ajp.2017.04.029. Epub 2017 May 15. Asian J Psychiatr. 2017. PMID: 28784374
The aim was to find the factor structures of MDD as per Montgomery and Asberg Depression Rating Scale (MADRS) and whether they predict escitalopram response. METHODS: In a longitudinal study at a tertiary institute in north India, 116 adult out-patients with non-psy …
The aim was to find the factor structures of MDD as per Montgomery and Asberg Depression Rating Scale (MADRS) and whether they predict es …
Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials.
Lam RW, Andersen HF, Wade AG. Lam RW, et al. Int Clin Psychopharmacol. 2008 Jul;23(4):181-7. doi: 10.1097/YIC.0b013e3282ffdedc. Int Clin Psychopharmacol. 2008. PMID: 18545055
Recent studies have compared escitalopram with duloxetine. Data from two randomized, double-blind studies that compared escitalopram (10-20 mg/day) and duloxetine (60 mg/day) were pooled and analysed for all patients and for the subsample of severely depressed patients [ba …
Recent studies have compared escitalopram with duloxetine. Data from two randomized, double-blind studies that compared escitalopram …
The BDNF Val(66)Met polymorphism is associated with escitalopram response in depressed patients.
El-Hage W, Vourc'h P, Gaillard P, Léger J, Belzung C, Ibarguen-Vargas Y, Andres CR, Camus V. El-Hage W, et al. Psychopharmacology (Berl). 2015 Feb;232(3):575-81. doi: 10.1007/s00213-014-3694-z. Epub 2014 Jul 31. Psychopharmacology (Berl). 2015. PMID: 25074447
METHODS: We included 187 Caucasian subjects with depression; 153 completed the 6-week study. Clinical evaluation was performed using the Montgomery and Asberg Depression Rating Scale (MADRS) before and after 3-6 weeks of treatment. ...
METHODS: We included 187 Caucasian subjects with depression; 153 completed the 6-week study. Clinical evaluation was performed using …
Prothrombotic platelet phenotype in major depression: downregulation by antidepressant treatment.
Lopez-Vilchez I, Serra-Millas M, Navarro V, Rosa Hernandez M, Villalta J, Diaz-Ricart M, Gasto C, Escolar G, Galan AM. Lopez-Vilchez I, et al. J Affect Disord. 2014 Apr;159:39-45. doi: 10.1016/j.jad.2014.02.022. Epub 2014 Feb 20. J Affect Disord. 2014. PMID: 24679387
METHODS: Modifications in a series of biomarkers of platelet and coagulation activation were evaluated in blood from 19 patients with a major depression disorder (MDD) at the time of diagnosis, and at 8 and 24 weeks of treatment with escitalopram. Response of blood …
METHODS: Modifications in a series of biomarkers of platelet and coagulation activation were evaluated in blood from 19 patients with a majo …
Pharmacogenetic Study of Serotonin Transporter and 5HT2A Genotypes in Autism.
Najjar F, Owley T, Mosconi MW, Jacob S, Hur K, Guter SJ, Sweeney JA, Gibbons RD, Cook EH, Bishop JR. Najjar F, et al. J Child Adolesc Psychopharmacol. 2015 Aug;25(6):467-74. doi: 10.1089/cap.2014.0158. J Child Adolesc Psychopharmacol. 2015. PMID: 26262902 Free PMC article. Clinical Trial.
RESULTS: Insistence on sameness and irritability symptoms significantly improved over the course of the 6 week treatment period (p<0.0001) in this open-label trial. There were no significant differences observed in the rate of symptom improvement over time across genoty …
RESULTS: Insistence on sameness and irritability symptoms significantly improved over the course of the 6 week treatment period (p<0.0001 …
A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
Trivedi MH, Cutler AJ, Richards C, Lasser R, Geibel BB, Gao J, Sambunaris A, Patkar AA. Trivedi MH, et al. J Clin Psychiatry. 2013 Aug;74(8):802-9. doi: 10.4088/JCP.13m08360. J Clin Psychiatry. 2013. PMID: 24021497 Clinical Trial.
The LS mean treatment difference in remitters was not statistically significant (1.2 [-1.6 to 4.0]; P = .4726). Among randomized participants, 49.4% (42/85) receiving placebo and 60.2% (53/88) receiving lisdexamfetamine dimesylate had 1 treatment-emergent adverse event, th …
The LS mean treatment difference in remitters was not statistically significant (1.2 [-1.6 to 4.0]; P = .4726). Among randomized part …